Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.

@article{Rmke2011ImmunogenicityAS,
  title={Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses.},
  author={Hans C. R{\"u}mke and H P Loch and Karel P M Hoppenbrouwers and Corinne Vandermeulen and Anne Malfroot and Klaus E Helm and Martine Douha and Paul Willems},
  journal={Vaccine},
  year={2011},
  volume={29 22},
  pages={3842-9}
}
BACKGROUND The MMRV combination vaccine, Priorix-Tetra™, is currently licensed in several European countries using a two-dose schedule in infants aged ≥9 months, with a preferred 6-week to 3-month interval between doses. This study was undertaken to generate safety and immunogenicity data for two doses of MMRV vaccine administered according to dose schedules using the shortest permitted interval of 4 weeks versus a longer interval of 12 months, which would allow flexible adaptation to local… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…